Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
STA Pharmaceutical announce a strategic partnership.
read more
WuXi STA, a subsidiary of WuXi AppTec, has opened a new continuous manufacturing (flow chemistry) plant at its Changzhou campus in China for large-scale active pharmaceutical ingredient (API) and advanced intermediate production.
read more
Monday, September 12, 2022
WuXi STA, a subsidiary of WuXi AppTec, announced the opening of a new sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its Wuxi city campus. Created in response to the increasing demand for complex injection ...
read more
WuXi STA, a subsidiary of WuXi AppTec, announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at its Changzhou campus.
read more
WuXi STA announced the opening of its large-scale oligonucleotide API manufacturing facility in Changzhou, China.
read more
STA Pharmaceutical announced its ASU in Shanghai and API process R&D and manufacturing facility in Changzhou, have successfully passed two inspections from the FDA.
read more
STA Pharmaceutical has signed an investment agreement with the government of Shanghai, Jinshan District to build a new R&D center.
read more
Tuesday, February 09, 2021
WuXi STA has agreed to purchase Bristol Myers Squibb’s manufacturing facility in Couvet, Switzerland.
read more
STA Pharmaceutical announced its partner, Ascletis has received approval from China Food and Drug Administration of its Category 1 new drug, Ganovo, to treat viral hepatitis C.
read more
STA Pharmaceutical and Antengene Corporation recently announced a strategic partnership for the CMC development and manufacturing of innovative oncology drugs
read more
Wednesday, March 06, 2019
STA Pharmaceutical, a subsidiary of WuXi AppTec, and Ark Biosciences announced a strategic partnership for CMC development and manufacturing.
read more
STA Pharmaceutical, a subsidiary of WuXi AppTec, and Dizal Pharmaceutical have announced a strategic partnership.
read more
Thursday, February 22, 2018
STA Pharmaceutical and Regulus Therapeutics have entered into an oligonucleotide synthesis collaboration agreement for research and mid-scale non-GMP/cGMP manufacturing.
read more
STA Pharmaceutical announced its Jinshan manufacturing facility in Shanghai, China has successfully passed an inspection by the EMA with no critical and no major findings.
read more
STA Pharmaceutical announces its API manufacturing facility at Jinshan has successfully passed its fourth inspection from the FDA – with no Form 483s issued.
read more